SNS Financial Group’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-4,126
| Closed | -$354K | – | 193 |
|
|
2022
Q4 | $354K | Buy |
4,126
+57
| +1% | +$4.51K | 0.05% | 142 |
|
|
2022
Q3 | $251K | Buy |
4,069
+42
| +1% | +$2.65K | 0.04% | 154 |
|
|
2022
Q2 | $249K | Buy |
4,027
+48
| +1% | +$2.97K | 0.03% | 159 |
|
|
2022
Q1 | $237K | Hold |
3,979
| – | – | 0.03% | 179 |
|
|
2021
Q4 | $289K | Hold |
3,979
| – | – | 0.03% | 180 |
|
|
2021
Q3 | $278K | Sell |
3,979
-71
| -2% | -$4.99K | 0.03% | 172 |
|
|
2021
Q2 | $279K | Buy |
4,050
+4
| +0.1% | +$267 | 0.04% | 172 |
|
|
2021
Q1 | $261K | Buy |
4,046
+191
| +5% | +$12.3K | 0.03% | 171 |
|
|
2020
Q4 | $225K | Buy |
3,855
+200
| +5% | +$12.1K | 0.03% | 176 |
|
|
2020
Q3 | $231K | Sell |
3,655
-20
| -0.5% | -$1.39K | 0.04% | 171 |
|
|
2020
Q2 | $283K | Sell |
3,675
-187
| -5% | -$14.3K | 0.05% | 145 |
|
|
2020
Q1 | $289K | Sell |
3,862
-278
| -7% | -$19.2K | 0.06% | 150 |
|
|
2019
Q4 | $269K | Sell |
4,140
-128
| -3% | -$8.34K | 0.05% | 177 |
|
|
2019
Q3 | $270K | Buy |
4,268
+65
| +2% | +$4.25K | 0.05% | 159 |
|
|
2019
Q2 | $284K | Sell |
4,203
-56
| -1% | -$3.68K | 0.05% | 159 |
|
|
2019
Q1 | $277K | Sell |
4,259
-421
| -9% | -$28K | 0.06% | 147 |
|
|
2018
Q4 | $293K | Sell |
4,680
-20,260
| -81% | -$1.42M | 0.07% | 141 |
|
|
2018
Q3 | $1.93M | Sell |
24,940
-1,907
| -7% | -$144K | 0.46% | 45 |
|
|
2018
Q2 | $1.9M | Sell |
26,847
-28
| -0.1% | -$1.98K | 0.5% | 40 |
|
|
2018
Q1 | $2.03M | Sell |
26,875
-1,815
| -6% | -$144K | 0.55% | 37 |
|
|
2017
Q4 | $2.06M | Buy |
28,690
+21,722
| +312% | +$1.65M | 0.49% | 43 |
|
|
2017
Q3 | $564K | Buy |
6,968
+200
| +3% | +$15.3K | 0.14% | 100 |
|
|
2017
Q2 | $479K | Buy |
6,768
+483
| +8% | +$32.1K | 0.13% | 106 |
|
|
2017
Q1 | $427K | Buy |
6,285
+2,429
| +63% | +$171K | 0.11% | 114 |
|
|
2016
Q4 | $276K | Buy |
+3,856
| New | +$287K | 0.08% | 136 |
|
|
2016
Q2 | – | Sell |
-45,176
| Closed | -$4.15M | – | 131 |
|
|
2016
Q1 | $4.15M | Buy |
45,176
+1,984
| +5% | +$179K | 1.06% | 20 |
|
|
2015
Q4 | $4.37M | Buy |
43,192
+4,486
| +12% | +$467K | 1.08% | 20 |
|
|
2015
Q3 | $3.8M | Buy |
38,706
+1,454
| +4% | +$161K | 1.04% | 20 |
|
|
2015
Q2 | $4.36M | Buy |
+37,252
| New | +$4.07M | 1.32% | 17 |
|
Other funds holding GILD
SNS Financial Group's GILD Position: Q1 2023 in Review
SNS Financial Group sold out of Gilead Sciences (GILD) in Q1 2023, closing a stake of 4,126 shares — an estimated $354K sold.
SNS Financial Group first reported a position in GILD in Q2 2015 and held it in 29 quarters. The position peaked at $4.37M in Q4 2015. 1,736 funds tracked by Wall St. Rank hold GILD as of Q1 2023.
- SNS Financial Group reported no remaining Gilead Sciences position as of Q1 2023 after selling out during the quarter.
- SNS Financial Group sold 4,126 Gilead Sciences shares in Q1 2023, an estimated $354K.
- SNS Financial Group first reported a position in Gilead Sciences in Q2 2015 and held it in 29 quarters.
- SNS Financial Group's Gilead Sciences position peaked at $4.37M in Q4 2015.
- 1,736 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2023.
Based on SNS Financial Group's 13F filing for Q1 2023, filed 28 Apr 2023.